{
    "id": 263,
    "name": "kidney cancer",
    "source": "DOID",
    "definition": "A urinary system cancer that is located_in the kidney. [url:http\\://en.wikipedia.org/wiki/Kidney_cancer]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "3676",
        "11834"
    ],
    "termId": "DOID:263",
    "evidence": [
        {
            "id": 4387,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, renal cancer cell lines harboring a PIK3CB D1067V mutation demonstrated reduced sensitivity to GDC-0941-induced growth inhibition in culture (PMID: 26759240).",
            "molecularProfile": {
                "id": 4472,
                "profileName": "PIK3CB D1067V"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4509,
                    "pubMedId": 26759240,
                    "title": "Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110\u03b2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26759240"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6265,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DHA and Stivarga (regorafenib) synergistically inhibited survival of kidney cancer cells in culture and reduced tumor growth in kidney cancer cell line xenograft models (PMID: 26921392).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4107,
                "therapyName": "DHA + Regorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5514,
                    "pubMedId": 26921392,
                    "title": "Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26921392"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7488,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human kidney cancer cell line harboring MTOR E1799K demonstrated hypersensitivity to Rapamune (sirolimus) induced growth inhibition in culture (PMID: 24631838).",
            "molecularProfile": {
                "id": 3193,
                "profileName": "MTOR E1799K"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1953,
                    "pubMedId": 24631838,
                    "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24631838"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7725,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S-222611 inhibited tumor growth of human kidney cancer cells expressing EGFR in cell line xenograft models (PMID: 24837299).",
            "molecularProfile": {
                "id": 1102,
                "profileName": "EGFR positive"
            },
            "therapy": {
                "id": 1048,
                "therapyName": "S-222611",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1835,
                    "pubMedId": 24837299,
                    "title": "Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24837299"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8758,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 inhibited growth of 3/4 tested renal cancer cell lines harboring PBRM1 inactivating mutations in culture, with inhibitor sensitivity associating with dependence on EZH2 catalytic activity (PMID: 26552009).",
            "molecularProfile": {
                "id": 21543,
                "profileName": "PBRM1 inact mut"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6732,
                    "pubMedId": 26552009,
                    "title": "SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26552009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8941,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3023414 inhibited proliferation of renal cancer cells harboring PTEN inactivating mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).",
            "molecularProfile": {
                "id": 2095,
                "profileName": "PTEN inact mut"
            },
            "therapy": {
                "id": 1069,
                "therapyName": "LY3023414",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6792,
                    "pubMedId": 27439478,
                    "title": "Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27439478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9079,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Sutent (sunitinib) inhibited tumor growth in patient-derived xenograft models of renal cancer harboring VHL V155fs (referred to as V155fs*4) (PMID: 26487278).",
            "molecularProfile": {
                "id": 26715,
                "profileName": "VHL V155fs"
            },
            "therapy": {
                "id": 4874,
                "therapyName": "Sunitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6896,
                    "pubMedId": 26487278,
                    "title": "Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26487278"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10961,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with kidney cancer demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5739,
                "therapyName": "OPB-111077",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8960,
                    "pubMedId": null,
                    "title": "Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B118.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11012,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-014 inhibited growth of HAVCR1-positive renal cancer cells in culture, resulted in anti-tumor activity and improved survival in cell line xenograft models (PMID: 27671527).",
            "molecularProfile": {
                "id": 27883,
                "profileName": "HAVCR1 positive"
            },
            "therapy": {
                "id": 5774,
                "therapyName": "CDX-014",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8982,
                    "pubMedId": 27671527,
                    "title": "Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27671527"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11039,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CVX-241 did not improve overall survival in a mouse model of resected renal cancer (PMID: 27651308).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5619,
                "therapyName": "CVX-241",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8822,
                    "pubMedId": 27651308,
                    "title": "Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27651308"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11040,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CVX-060 and Sutent (sunitinib) demonstrated a trend improved overall survival compared to single agent Sutent (sunitinib) in mouse models of unresected and resected renal cancer, however, also demonstrated increased toxicity (PMID: 27651308).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5622,
                "therapyName": "CVX-060 + Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8822,
                    "pubMedId": 27651308,
                    "title": "Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27651308"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12084,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ISTH0047 reduced lung metastasis, but not primary tumor growth, in a mouse model of metastatic kidney cancer (PMID: 28911087).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6256,
                "therapyName": "ISTH0047",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10015,
                    "pubMedId": 28911087,
                    "title": "An antisense oligonucleotide targeting TGF-\u03b22 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28911087"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18507,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human kidney cancer cell line expressing MTOR Y1974H demonstrated sensitivity to Rapamune (sirolimus) treatment in culture (PMID: 29118224).",
            "molecularProfile": {
                "id": 33382,
                "profileName": "MTOR Y1974H"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 263,
                "name": "kidney cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12392,
                    "pubMedId": 29118224,
                    "title": "Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR-Activating Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29118224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00184015",
            "title": "Bortezomib and Bevacizumab (\"BB-mib-mab\") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)",
            "phase": null,
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00375674",
            "title": "A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer",
            "phase": null,
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00923130",
            "title": "Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1122,
                    "therapyName": "Bevacizumab + Ixabepilone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01005797",
            "title": "Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1131,
                    "therapyName": "Panobinostat + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01184326",
            "title": "An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1806,
                    "therapyName": "Everolimus + Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01217931",
            "title": "Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01218867",
            "title": "Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 984,
                    "therapyName": "Anti-VEGFR2 CAR CD8 lymphocytes",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01480154",
            "title": "Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1393,
                    "therapyName": "Hydroxychloroquine + MK2206",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01497444",
            "title": "Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1320,
                    "therapyName": "Evofosfamide + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01727089",
            "title": "Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 1243,
                    "therapyName": "Bevacizumab + Carotuximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02077933",
            "title": "Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1384,
                    "therapyName": "Alpelisib + Everolimus",
                    "synonyms": null
                },
                {
                    "id": 1385,
                    "therapyName": "Alpelisib + Everolimus + Exemestane",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02318771",
            "title": "Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02460224",
            "title": "Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2887,
                    "therapyName": "LAG525",
                    "synonyms": null
                },
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02504892",
            "title": "Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02643303",
            "title": "A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3385,
                    "therapyName": "Durvalumab + Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02899078",
            "title": "Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3198,
                    "therapyName": "Ibrutinib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02964078",
            "title": "Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4165,
                    "therapyName": "Aldesleukin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03829501",
            "title": "Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7826,
                    "therapyName": "Atezolizumab + KY1044",
                    "synonyms": null
                },
                {
                    "id": 7825,
                    "therapyName": "KY1044",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04134312",
            "title": "A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6889,
                    "therapyName": "MVA-BN-Brachyury",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04148937",
            "title": "A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8894,
                    "therapyName": "LY3475070",
                    "synonyms": null
                },
                {
                    "id": 8895,
                    "therapyName": "LY3475070 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04259450",
            "title": "Study to Assess AFM24 in Advanced Solid Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5856,
                    "therapyName": "AFM24",
                    "synonyms": null
                }
            ]
        }
    ]
}